[go: up one dir, main page]

JP2000501095A - ２’‐［［４’‐ハロ‐［１，１’‐ビフェニル］‐４‐イル］メチル］‐５’‐メチル‐スピロ［シクロペンタン‐１，７’（８’Ｈ）‐［３Ｈ］イミダゾ［２，１‐ｂ］プリン］‐４’（５’Ｈ）‐オン類 - Google Patents

２’‐［［４’‐ハロ‐［１，１’‐ビフェニル］‐４‐イル］メチル］‐５’‐メチル‐スピロ［シクロペンタン‐１，７’（８’Ｈ）‐［３Ｈ］イミダゾ［２，１‐ｂ］プリン］‐４’（５’Ｈ）‐オン類

Info

Publication number
JP2000501095A
JP2000501095A JP9520543A JP52054397A JP2000501095A JP 2000501095 A JP2000501095 A JP 2000501095A JP 9520543 A JP9520543 A JP 9520543A JP 52054397 A JP52054397 A JP 52054397A JP 2000501095 A JP2000501095 A JP 2000501095A
Authority
JP
Japan
Prior art keywords
methyl
compound
spiro
biphenyl
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9520543A
Other languages
English (en)
Japanese (ja)
Inventor
エイ． マックキトリック，ブライアン
タルシアン，ディーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2000501095A publication Critical patent/JP2000501095A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP9520543A 1995-11-28 1996-11-26 ２’‐［［４’‐ハロ‐［１，１’‐ビフェニル］‐４‐イル］メチル］‐５’‐メチル‐スピロ［シクロペンタン‐１，７’（８’Ｈ）‐［３Ｈ］イミダゾ［２，１‐ｂ］プリン］‐４’（５’Ｈ）‐オン類 Pending JP2000501095A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56371795A 1995-11-28 1995-11-28
US08/563,717 1995-11-28
PCT/US1996/018550 WO1997019947A1 (en) 1995-11-28 1996-11-26 2'-[[4'-HALO-[1,1'-BIPHENYL]-4-YL]METHYL]-5'-METHYL-SPIRO[CYCLOPENTANE-1,7'(8'H)-[3H]IMIDAZO[2,1-b]PURIN]-4'(5'H)-ONES

Publications (1)

Publication Number Publication Date
JP2000501095A true JP2000501095A (ja) 2000-02-02

Family

ID=24251614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9520543A Pending JP2000501095A (ja) 1995-11-28 1996-11-26 ２’‐［［４’‐ハロ‐［１，１’‐ビフェニル］‐４‐イル］メチル］‐５’‐メチル‐スピロ［シクロペンタン‐１，７’（８’Ｈ）‐［３Ｈ］イミダゾ［２，１‐ｂ］プリン］‐４’（５’Ｈ）‐オン類

Country Status (8)

Country Link
EP (1) EP0863902A1 (es)
JP (1) JP2000501095A (es)
AR (1) AR004752A1 (es)
AU (1) AU1055597A (es)
CA (1) CA2237956A1 (es)
CO (1) CO4480029A1 (es)
WO (1) WO1997019947A1 (es)
ZA (1) ZA969888B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
CN1434825A (zh) 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
WO2001047934A1 (de) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Isoxazolopyrimidinone und ihre verwendung
ES2231311T3 (es) 1999-12-24 2005-05-16 Bayer Healthcare Ag Triazolotriazinonas y su uso.
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5939419A (en) * 1993-02-26 1999-08-17 Schering-Plough Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them

Also Published As

Publication number Publication date
MX9804198A (es) 1998-10-31
EP0863902A1 (en) 1998-09-16
AU1055597A (en) 1997-06-19
WO1997019947A1 (en) 1997-06-05
ZA969888B (en) 1997-05-26
CA2237956A1 (en) 1997-06-05
AR004752A1 (es) 1999-03-10
CO4480029A1 (es) 1997-07-09

Similar Documents

Publication Publication Date Title
US5824683A (en) 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
EP1165558B1 (en) Derivatives of pyrimido[6,1-a]isoquinolin-4-one
EP0538332B1 (en) Polycyclic guanine derivatives
EP1246623B1 (en) Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
AU2010257449B2 (en) New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
US6747035B2 (en) 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
JPH08507068A (ja) ２−ベンジル−多環式グアニン誘導体およびそれらの製造方法
JP2011526295A (ja) ５員および６員複素環化合物
JP2001502717A (ja) ナフチリジン誘導体
OA13295A (en) Compounds specific to adenosine A1, A2a, and A3 receptor and uses thereof.
JP2011526294A (ja) ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物
JP2003525295A (ja) １，５−二置換−３，４−ジヒドロ−１ｈ−ピリミド［４，５−ｄ］ピリミジン−２−オン化合物およびｃｓｂｐ／ｐ３８キナーゼ介在疾患の治療におけるその使用
KR20130083389A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
JP2002543199A (ja) ホスホジエステラーゼＩＶを阻害する１−アミノトリアゾロ［４，３−ａ］キナゾリン−５−オン、および／または−５−チオン
WO2021067584A1 (en) Methods of treatment for alpha-1 antitrypsin deficiency
JPH11501926A (ja) ６−アリールピラゾロ［３，４−ｄ］ピリミジン−４−オン、並びにその組成物及び使用法
JP4749545B2 (ja) 置換トリアゾロ−ピリダジン誘導体、該誘導体から製造される医薬組成物
JPH08510221A (ja) Ａｍｐａ拮抗薬およびそれを用いての治療方法
JP6633246B2 (ja) ヒトｐｄｅ１阻害薬として有用なトリアゾロピラジノン誘導体
CZ286814B6 (cs) Pyridazino/4,5-b/chinoliny, způsob jejich přípravy a farmaceutická kompozice tyto chinoliny obsahující
JP2000501095A (ja) ２’‐［［４’‐ハロ‐［１，１’‐ビフェニル］‐４‐イル］メチル］‐５’‐メチル‐スピロ［シクロペンタン‐１，７’（８’Ｈ）‐［３Ｈ］イミダゾ［２，１‐ｂ］プリン］‐４’（５’Ｈ）‐オン類
WO1997019079A1 (en) IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
JP3046851B2 (ja) ２，４，８−三置換−３Ｈ，６Ｈ−１，４，５ａ，８ａ−テトラアザアセナフチレン−３，５（４Ｈ）−ジオン類
JPH04270222A (ja) 脳機能改善剤
MXPA98004198A (es) 2'[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7'(8'h)-[3h imidazo[2,1-b]purin]4'(5'h)-onas

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070903